** New website coming soon **
To save and improve the lives of mothers’ and babies’ worldwide through randomised studies enrolling 5,000 to 50,000 or more.
To work with other organisations, clinicians, researchers, parents, policymakers and funders around the world to identify key questions to test treatments that may save lives and reduce disability - and to answer those questions faster and more reliably than ever before.
Our mission is to build a coalition with organisations, researchers, professionals, parents, funders, policymakers and individuals around the globe to improve healthy survival for mothers and babies by
Studies this large will also yield considerably more precise estimates of differences in disability in survivors than would have normally been possible.
However, such studies will need many centres and highly streamlined processes to enable fast recruitment with minimal data collection, as in recent randomised mega-studies in COVID-19.
Compared with the first 10 years of this century 50,000 more very premature babies will survive without major disability in the next 10 years - if caregivers worldwide simply delay cord clamping for 60 seconds or more in babies who do not need immediate resuscitation.
That equates to 13 per day - or one more survivor without major disability every 2 hours.
These forecasts are based on the 2 year follow up results of APTS - the Australian Placental Transfusion Study - which were published in The Lancet Child and Adolescent Health in December 2021.
LEARN MORE ABOUT APTS
APTS enrolled 1531 babies born before 30 weeks gestation in 25 centres in 7 countries in the largest-ever randomised trial of delayed versus immediate cord clamping. By reliably answering an important question it will improve thousands of children’s and families’ lives.
Yet APTS took 12 years - from 2009 to 2021 - to answer that question. Can we do better?
Could we have helped more babies and families sooner? What can perinatal trials learn from the multi-arm multi-stage adaptive randomised trials and individual participant data prospective meta-analyses (IPD PMAs) that rapidly identified effective interventions in COVID-19?
By collaborating globally and integrating digital technology, can we answer important questions with randomised studies run at least ten times larger and faster than APTS - for example by recruiting 250 centres instead of just 25 - and at one-tenth the cost?
You can stay in touch by